NR4A1 and breast cancer: Among biomarker-driven therapies, the PI3K inhibitor alpelisib in combination with fulvestrant prolonged progression-free survival (PFS) in PIK3CA-mutated, hormone receptor (HR)-positive (+), and human epidermal growth factor receptor 2 (HER2)-negative (−) BC [6].